Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Autor: Gerd K. Rosenkranz, George Apostol, Alessandra Murgia, Christian Wolf, Vincent des Portes, Randi J Hagerman, Elizabeth Berry-Kravis, Barbara Koumaras, Andrew C. Stanfield, Sébastien Jacquemont, Florian Von Raison

Publikováno v: Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Scientific Reports
Scientific reports, vol 8, iss 1
Hagerman, R, Jacquemont, S, Berry-Kravis, E, Des Portes, V, Stanfield, A, Koumaras, B, Rosenkranz, G, Murgia, A, Wolf, C, Apostol, G & von Raison, F 2018, ' Mavoglurant in Fragile X Syndrome : Results of two open-label, extension trials in adults and adolescents ', Scientific Reports, vol. 8, no. 1, pp. 16970 . https://doi.org/10.1038/s41598-018-34978-4
Scientific reports, vol. 8, no. 1, pp. 16970

Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64f802041339772bf5d7fcef235cf245
https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46

Long-term effects of rivastigmine capsules in patients with traumatic brain injury

Autor: Xiangyi Meng, Philip D. Harvey, Douglas I. Katz, Steven G. Potkin, David B. Arciniegas, Patricio F. Reyes, Jonathan M. Silver, Ibrahim Gunay, Barbara Koumaras

Publikováno v: Brain Injury. 23:123-132

To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.Patients with traumatic brain injury (TBI) and persistent cognitive impairment who ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a61cc38af1ca449f13b6fdf4a12f679a
https://doi.org/10.1080/02699050802649696

Effects of rivastigmine on cognitive function in patients with traumatic brain injury

Autor: Barbara Koumaras, Dario Mirski, Michael Chen, Jonathan M. Silver, Philip D. Harvey, David B. Arciniegas, Patricio F. Reyes, Ibrahim Gunay, Steven G. Potkin, D. Warden, Douglas I. Katz

Publikováno v: Neurology. 67:748-755

Objective: To compare the efficacy and safety of rivastigmine (3 to 6 mg/day) vs placebo over 12 weeks in patients with traumatic brain injury and persistent cognitive impairment. Methods: This prospective, randomized, double-blind, placebo-controlle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff27e7b662b45ed3627581c02847113f
https://doi.org/10.1212/01.wnl.0000234062.98062.e9

The Use of the Occupational Disruptiveness Scale of the Neuropsychiatric Inventory-Nursing Home Version to Measure the Impact of Rivastigmine on the Disruptive Behavior of Nursing Home Residents With Alzheimer’s Disease

Autor: Barbara Koumaras, Hind T. Hatoum, Dario Mirski, Swu-Jane Lin, Stephen Arcona, Simu K. Thomas

Publikováno v: Journal of the American Medical Directors Association. 6:238-245

Objectives The Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) was used to study the impact of rivastigmine (Exelon; Novartis Pharmaceuticals Corporation, East Hanover, NJ), on occupational disruptiveness (OD), a proxy measure for profession

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e10b597dd30ab0cd54bb44b02a380cf
https://doi.org/10.1016/j.jamda.2005.04.003

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

Autor: Peter M. Aupperle, Barbara Koumaras, Michael Chen, Adrian L. Rabinowicz, Dario Mirski

Publikováno v: Current Medical Research and Opinion. 20:1605-1612

To evaluate the safety and efficacy of long-term treatment with rivastigmine (3-12 mg/day) and its effects on neuropsychiatric and behavioral disturbances in nursing home patients with moderate to severe probable Alzheimer's disease (AD).A prospectiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0baf951fa60e535e4710ab9eb4422c2c
https://doi.org/10.1185/030079904125004204